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Abstract
Background—The incidence of hepatitis C virus (HCV) and hepatocellular carcinoma (HCC) is
increasing. The purpose of this study is to establish baseline survival in a medically-underserved
population and to evaluate the effect of HCV seropositivity on our patient population.
Materials and Methods—We reviewed clinicopathologic parameters from a prospective tumor
registry and medical records from the Harris County Hospital District (HCHD). Outcomes were
compared using Kaplan-Meier survival analysis and log-rank tests.
Results—A total of 298 HCC patients were identified. The median survival for the entire cohort
was 3.4 mo. There was no difference in survival between the HCV seropositive and the HCV
seronegative groups (3.6 mo versus 2.6 mo, P = 0.7). Patients with a survival <1 mo had a
significant increase in αfetoprotein (AFP), international normalized ratio (INR), model for end-
stage liver disease (MELD) score, and total bilirubin and decrease in albumin compared with
patients with a survival ≥1 mo.
Conclusions—Survival for HCC patients in the HCHD is extremely poor compared with an
anticipated median survival of 7 mo reported in other studies. HCV seropositive patients have no
survival advantage over HCV seronegative patients. Poorer liver function at diagnosis appears to
be related to shorter survival. Further analysis into variables contributing to decreased survival is
needed.
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INTRODUCTION
The incidence of hepatocellular carcinoma (HCC) in the United States has risen to 4.1 per
100,000 from 1.6 per 100,000 over the last 30 y. Although Asian/Pacific Islanders have the
highest age-adjusted incidence of HCC, the fastest rise in incidence rates in the last 15 y was
seen in American Indian/Alaska natives, followed by African-Americans, Caucasians, and
Hispanics [1]. With approximately 600,000 new cases reported worldwide each year, HCC
remains a significant, global healthcare issue [2].
Along with alcohol abuse, hepatitis B (HBV) and hepatitis C virus (HCV) seropositivity are
the leading risk factors for HCC. In the United States, effective HBV vaccination programs
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have resulted in HCV infection being largely responsible for the dramatic rise in the
incidence of HCC [3].
Both HBV and HCV can cause carcinogenesis by hepatic fibrosis. HBV, however, is a DNA
virus that can integrate into the hepatocyte DNA. This results in genomic instability and
provides an additional pathway for tumorigenesis [4]. Since HCV causes tumorigenesis by
hepatic fibrosis, HCV seropositive patients with HCC tend to have more advanced cirrhosis
and poorer liver function than patients with HBV-related HCC. While no significant
difference in survival has been identified in HBV-related HCC and HCV-related HCC, some
have noted that the HCV positive patients do better with transplantation as opposed to
resection [5], presumably due to greater liver function capacity postoperatively.
With a population approaching 4 million people, Harris County is the largest county in
Texas and one of the largest counties in the United States. The Harris County Hospital
District (HCHD) is one of the largest public hospital districts in the United States, with more
than 240,000 in-patient days per year. As a county hospital system in Texas, HCHD
primarily serves the indigent, uninsured, and underinsured. This translates into a patient
population that is mostly minority, largely socioeconomically disadvantaged, and with a
significant immigrant faction.
Currently there are an estimated 480,000 carriers of HCV in the state of Texas and, similar
to worldwide trends, the incidences of HCV, HBV, and HCC appear to be increasing. We
undertook this project to evaluate the baseline survival of patients with HCC within the
HCHD system. These patients often lack comprehensive primary care and access to
screening modalities and therefore present with advanced disease. Since the rate of survival
in patients with HCC is directly related to early detection [6], we expect to see poor survival
data in this cohort. Additionally, we investigated the association of HCV seropositivity on
survival in this unique cohort.
METHODS
The paper and electronic medical records of HCHD patients with a diagnosis of HCC from
1999 to 2009 were reviewed. Patient demographics, αfetoprotein (AFP) at diagnosis,
albumin at diagnosis, international normalized ratio (INR) at diagnosis, total bilirubin at
diagnosis, platelet count at diagnosis, model for end-stage liver disease score (MELD) at
diagnosis, HBV status, HCV status, stage at diagnosis, and length of survival were recorded.
When clinicopathologic and stage data could not be found, the patients were not excluded
from the study, but the missing data were omitted from the analysis.
Survival was determined as the difference between the date of diagnosis and the date of
death, confirmed by the Social Security Death Index. If the date of death could not be
verified, the date of last contact in the HCHD system was used. Diagnosis was made by one
of three methods: pathologic confirmation, the presence of a liver mass with an AFP greater
than or equal to 400 ng/mL, or a progressively enlarging liver mass in the setting of cirrhosis
in which the clinical picture is consistent with HCC. Survival analysis was performed using
the Kaplan-Meier method with differences determined by the log rank test. Significance was
defined as P < 0.05.
RESULTS
The medical records and tumor registry for 298 HCC patients was reviewed. The entire
cohort was predominately minority: 35% African-American, 35% Hispanic, 14% Asian, and
16% Caucasian. Although funding information was unknown for 62% of the cohort, 33% of
patients were “self-pay,” i.e., they had no private or government-sponsored health insurance,
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and 5% of patients had Medicaid or Medicare. A total of 183 were HCV seropositive (61%)
and 115 seronegative (39%). The HCV seropositive group had a significantly higher number
of females than the HCV negative group (Table 1). The composition by race and stage also
showed significant differences. More African-Americans were seen in the HCV positive
group and more Asians in the HCV negative group. Both groups had greater than 60% of
patients who presented with either stage III or stage IV disease.
Comparing the AFP, total bilirubin, INR, albumin, MELD score, and platelets at diagnosis,
only the platelet count had a statistically significant difference (Table 2). The mean platelet
count for the HCV seropositive group was 173, while the HCV seronegative group had a
mean platelet count of 236 (P = 0.001).
Approximately 29% of patients in the cohort received some sort of therapy for HCC: 19%
received intravenous or oral chemotherapy, 8% received transarterial chemoembolization,
and 5% underwent resection.
The entire group had an overall median survival of 3.4 mo (range 0 to 63.8 mo) after the
diagnosis of HCC was made (Table 3). The median survival for HCV seropositive patients
was 3.6 mo (range 0–54.7 mo) and 2.9 mo for HCV seronegative patients (range 0–63.8
mo). There is no significant difference between these two groups (P = 0.7) (Fig. 1A, Table
4).
Comparing survival of all patients by stage, there was a significant difference seen (P =
0.0046) (Fig. 1B, Table 3). Patients with stages I and II disease at presentation had a median
survival of 6.7 mo (range 0–63.8 mo) and 7.7 mo (range 0.1–44.1 mo), respectively. This
decreased to 3.5 mo (range 0–62.2 mo) and 1.7 mo (range 0–49.8 mo) for patients who
presented with stage III and stage IV disease (Fig. 1B).
Due to the observation that median survival for the entire cohort was much lower than
expected, we examined those patients with survival less than 1 month (LOS < 1 mo) and
compared that subgroup with those whose survival was greater than or equal to 1 mo (LOS
≥ 1 mo). There was no difference between groups for stage, gender, race, or age (Table 4).
Serum AFP, total bilirubin, INR, albumin, MELD score, and platelets for the LOS < 1
month group were all significantly different from LOS ≥ 1 mo (see Table 5).
DISCUSSION
Our series reports a far lower rate of both surgical therapy and median survival than
previously published studies. The SHARP trial, which enrolled Childs’ A cirrhotics with
advanced disease who were not candidates for or failed resection and locoregional therapies,
reported an overall median survival of 7.9 mo in the placebo group (those not given
sorafenib) [7]. Kim et al. recently reported the results of a large SEER HCC study in which
the median survival for all patients diagnosed this past decade (n = 9953) was 7 mo [8]. The
median survival for all patients in these two studies is similar to the survival for the stages I
and II patients in our cohort. The poor outcome for all patients regardless of stage suggests
that either the HCHD patients present with more advanced HCC, are not effectively
screened, receive fewer therapies for HCC, or have a greater degree of medical comorbidity
that negatively affects survival (Table 6).
Indeed, our cohort has very high AFP levels at diagnosis (median 30,689 and 18,076 in
HCV positive and negative groups, respectively). The placebo arm of the SHARP trial had a
median baseline AFP of 99, with a range from 0 to 500,000. This suggests a significant
tumor burden at diagnosis and may provide a partial explanation for the poorer survival
outcomes seen.
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The HCHD has no formal screening regimens and we do not know what percentage of our
patients received screening. Anecdotally, most patients in our cohort were first found to
have a liver mass in the emergency room, further demonstrating that screening the
population is not widespread. The American Association for the Study of Liver Disease
recommends that surveillance for chronic HCV and/or HBV seropositive patients with
cirrhosis should consist of biannual liver ultrasound and serum AFP measurements [9].
However, in the U.S., these screening recommendations are not routinely followed. There
are no current United States Preventative Services Task Force (USPSTF) recommendations
for HCC screening, and the last update was 2004. Nor does the USPSTF recommend
screening for HBV or HCV in the adult population at low risk for disease (current grade D
recommendation) and also those who are high risk for disease (grade I recommendation)
[10, 11]. Since resection and transplantation are the only curative therapies for HCC, early
diagnosis is key for survival. Multiple studies have shown increased survival with screening
programs aimed at high risk patients [12, 13]. The data on the cost-effectiveness of biannual
or annual screening of cirrhoticswith ultrasound and AFP remains controversial. This
underscores the need for data to support a cost effective screening program in the United
States.
In the Western Hemisphere, 30%–40% of patients diagnosed with hepatocellular carcinoma
undergo treatments with curative intent. Due to widespread screening in the Eastern
Hemisphere, 60%–90% of HCC patients in some developed countries, i.e., Japan, undergo
treatment with curative intent [14]. Kim et al. found that nearly 72% of patients received no
surgical intervention, while 6% underwent ablation/destruction procedures and 23%
underwent resection/transplantation. In our cohort, only 5% of patients underwent treatment
with curative intent (resection, in this case). The remainder of the patients treated for HCC
received chemotherapy or TACE, both of which are not potentially curative. Intravenous
chemotherapy, including doxorubicin, cisplatin, gemcitabine, and 5-FU, has not been shown
to improve survival in patients with HCC. It is important to note that a number of patients in
the present study were seen prior to FDA approval of the oral tyrosine kinase inhibitor
sorafenib (November 2007). In terms of curative treatments, the HCHD is able to offer
resection and ablation; transplantation services are not provided. Chemotherapy and TACE
are also provided. This underscores the need for an active screening program in the HCHD
for high risk patients so that HCC can be found at stages in which curative therapies may be
employed.
We do not have data to suggest that our patients have more medical comorbidities than other
studies’ cohorts. Future investigation into the prevalence of coronary artery disease,
diabetes, and other medical problems would be useful to evaluate if greater medical
comorbidities partially explain the poorer survival in our cohort.
With respect to the significant clinicopathologic values, the LOS < 1 month group had
significantly decreased albumin and increased AFP, total bilirubin, MELD score, and INR
compared to the LOS ≥ 1 month group. These laboratory values likely indicate an advanced
degree of liver disease and cirrhosis, which, in combination with a presumably high tumor
burden as indicated by the high AFP levels, may account for the decreased survival in that
group. It is unclear at this time how to address the problem of patients presenting with
concomitant end-stage liver disease and HCC. Advanced liver disease is likely to be a
significant factor contributing to the entire cohort’s poor survival.
This is a retrospective study with inherent limitations and biases. As with any retrospective
cohort study, disadvantages include limited control over the approach to sampling the
population and over the nature and quality of the predictor variables. As these data come
from a prospectively collected tumor registry, there is no a priori hypothesis, and the
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opportunity for unsystematic data collection is significant. Since there was no randomization
between HCV seropositive and HCV seronegative patients, confounding variables could
also be imbalanced.
Since the incidence of HCC is increasing, the poor overall survival of HCC patients detailed
in this study and other recent studies is concerning. Coupled with the fact that effective
screening guidelines are lacking and available treatments are marginally effective, HCC is
likely to remain a significant cause of cancer mortality. Worldwide, curative treatment
options include resection, transplantation, and ablation. These all require identifying the
tumor at an early stage in a patient with adequate liver function. Aggressive screening
programs in the Eastern Hemisphere have been implemented and appear to have increased
the portion of patients who are surgical candidates. Investigation into the cost and
effectiveness of HCC screening programs in the U.S. is needed.
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FIG. 1.
(A) Kaplan-Meier survival curve comparing patients by HCV status. (B) Kaplan-Meier
survival curve comparing patients by stage.
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TABLE 2
Median Laboratory Values at Presentation
HCV negative (IQR) HCV positive (IQR) P
α-Fetoprotein 526 (19–6,778) 693 (38–10,631) 0.167
Total bilirubin 1.4 (0.8–2.8) 1.6 (0.9–3.0) 0.677
INR 1.3 (1.1–1.5) 1.3 (1.2–1.5) 0.494
Albumin 2.8 (2.8–3.2) 2.6 (2.1–3.1) 0.888
Platelets 239 (105–319) 138 (93–211) 0.001
MELD score 10 (6–15) 12 (8–16) 0.058
IQR = interquartile range (25th–75th percentile).
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TABLE 3
Median Survival, in Months (range mo)
Overall 3.4 (0–63.8)
Stage
 I 6.7 (0–63.8)
 II 7.2 (0.1–44.1)
 III 3.5 (0–62.2)
 IV 1.7 (0–49.8)
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TABLE 4
Median Survival in HCV Seropositive and Seronegative Patients (range, mo)
HCV patient status
P valueNegative Positive
Overall 2.9 (0–63.8) 3.6 (0–54.7) 0.7
Stage
 I 7.4 (0–63.8) 6.1 (0.7–45.6)
 II 6.3 (0–22.5) 8.0 (0.1–44.1)
 III 7.3 (0–44.1) 3.3 (0–47.4)
 IV 1.5 (0–34.9) 2.3 (0–36.6)
Gender
 Male 2.1 (0.1–62.2) 3.4 (0–54.7)
 Female 8.3 (0.1–63.8) 9.4 (0–48.2)
Race
 Caucasian 2.0 (0–29.7) 4.8 (0.1–32.0)
 African-American 2.9 (0–16.2) 3.1 (0–45.6)
 Hispanic 5.1 (0–63.8) 4.3 (0–28.5)
 Asian 1.9 (0.1–62.2) 3.7 (0–54.7)
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TABLE 5
Characteristics of Patients with Survival Less Than and Greater Than 1 Month
LOS < 1 mo LOS ≥ 1 mo P value
Number 72 226
Median age 53 54 0.444
Stage 0.114
 I 6 (9.1%) 45 (21.2%)
 II 11 (16.7%) 28 (13.2%)
 III 23 (34.8%) 70 (33.0%)
 IV 26 (39.4%) 69 (32.5%)
Gender 0.444
 Male 63 (87.5%) 180 (79.6%)
 Female 9 (12.5%) 46 (20.4%)
Race 0.277
 Caucasian 13 (18.1%) 33 (14.6%)
 African-American 27 (37.5%) 76 (33.6%)
 Hispanic 23 (31.9%) 85 (37.6%)
 Asian 9 (12.5%) 32 (14.2%)
LOS = length of survival.
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TABLE 6
Median Laboratory Values at Presentation in Patients with Survival Less Than and Greater Than 1 Month
LOS < 1 mo (IQR) LOS ≥ 1 mo (IQR) P
α-Fetoprotein 6693 (111–37,722) 286 (27–4172) 0.002
Total bilirubin 2.7 (1.4–6.2) 1.4 (0.8–2.5) 0.005
INR 1.5 (1.3–1.8) 1.3 (1.1–1.5) 0.003
Albumin 2.2 (1.8–2.8) 2.8 (2.3–3.2) 0.003
Platelets 135 (98–213) 164 (97–275) 0.064
MELD score 15 (9–21) 11 (8–15) 0.002
IQR = interquartile range (25th–75th percentile); LOS = length of survival.
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